Skip to content

A prospective observational study to evaluate the safety of robot-assisted esophagectomy using the da Vinci SP

A prospective observational study to evaluate the safety of robot-assisted esophagectomy using the da Vinci SP - An observational study of robot-assisted esophagectomy using the da Vinci SP

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000060119
Enrollment
10
Registered
2025-12-18
Start date
2025-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esohageal cancer

Interventions

None listed

Sponsors

Osaka Keisatsu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Esophageal cancer patients who are eligible for robotic-assisted esophagectomy using a da Vinci SP based on preoperative examination. 2) Patients who are willing to follow the research protocol. 3) Patients have signed a consent form for participation in the study that has been approved by our institution's ethical review board. However, a proxy may sign only if the patient is unable to sign due to a physical disability.

Exclusion criteria

Exclusion criteria: 1) Women who may be pregnant or who are breastfeeding. 2) Patients with psychiatric illness or symptoms who are deemed to make it difficult to participate in the study. 3) Patients who are deemed to be inappropriate for endoscopic surgery. 4) Patients with serious medical conditions that the principal investigator or co-researcher deems inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Completion rate of robotic-assisted esophagectomy using da Vinci SP

Countries

Japan

Contacts

Public ContactYujiro Nakahara

Osaka Keisatsu Hospital Department of Gastroenterological Surgery

nakahara.yujiro75@oim.or.jp06-6771-6051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026